HealthNovo Nordisk Suffers Major Setback as Experimental Heart Drug Fails Late-Stage Clinical Trial
One of today's most important global health and pharmaceutical stories is Novo Nordisk's announcement that its experimental cardiovascular drug, ziltivekimab, failed a major Phase 3 clinical trial. The drug did not significantly reduce the risk of heart attacks, strokes, or cardiovascular deaths, dealing a setback to the company's strategy of expanding beyond diabetes and obesity treatments.
2 min read · 2 Aug









